Its pharma division outperforms, and our only concern is the stock's high valuation.
Speculation that CEO Jeff Immelt may step down is a step in the right direction.
We could see more squeezes before the correction proceeds on its downward course.
The company is taking meaningful steps to address its recall situation.
Bank of America, Goldman and USB all report this week.
The put will likely expire worthless, but it will cushion any earnings surprises.
The stock is up as the Ukraine crisis lifts oil prices.
We ended up legging into the protective structure in NKE, so we'll explain exactly what that term means.
Nearly all of the major instruments are showing well-defined trendlines at lower levels, suggesting this will happen in the coming weeks.
An active week for the portfolio and the market produced a list of stocks we are watching into earnings.